EN ISO 14155:2011

SLOVENSKI STANDARD
01-april-2011
1DGRPHãþD
SIST EN ISO 14155-1:2009
SIST EN ISO 14155-2:2009
.OLQLþQHUD]LVNDYHPHGLFLQVNLKSULSRPRþNRY]DOMXGL'REUHNOLQLþQHSUDNVH,62

Clinical investigation of medical devices for human subjects - Good clinical practice (ISO
14155:2011)
Klinische Prüfung von Medizinprodukten an Menschen - Gute klinische Praxis (ISO
14155:2011)
Investigation clinique des dispositifs médicaux pour sujets humains - Bonnes pratiques
cliniques (ISO 14155:2011)
Ta slovenski standard je istoveten z: EN ISO 14155:2011
ICS:
11.040.01 Medicinska oprema na Medical equipment in general
splošno
2003-01.Slovenski inštitut za standardizacijo. Razmnoževanje celote ali delov tega standarda ni dovoljeno.

EUROPEAN STANDARD
EN ISO 14155
NORME EUROPÉENNE
EUROPÄISCHE NORM
February 2011
ICS 11.100.20 Supersedes EN ISO 14155-1:2009, EN ISO 14155-2:2009
English Version
Clinical investigation of medical devices for human subjects -
Good clinical practice (ISO 14155:2011)
Investigation clinique des dispositifs médicaux pour sujets Klinische Prüfung von Medizinprodukten an Menschen -
humains - Bonnes pratiques cliniques (ISO 14155:2011) Gute klinische Praxis (ISO 14155:2011)
This European Standard was approved by CEN on 10 December 2010.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European
Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national
standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation
under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same
status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland,
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.

EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION

EUROPÄISCHES KOMITEE FÜR NORMUNG

Management Centre: Avenue Marnix 17, B-1000 Brussels
© 2011 CEN All rights of exploitation in any form and by any means reserved Ref. No. EN ISO 14155:2011: E
worldwide for CEN national Members.

Contents Page
Foreword .3
Annex ZA .4
Annex ZB .5

Foreword
This document (EN ISO 14155:2011) has been prepared by Technical Committee ISO/TC 194 "Biological
evaluation of medical devices" in collaboration with Technical Committee CEN/TC 258 “Clinical investigation
of medical devices” the secretariat of which is held by DIN.
This European Standard shall be given the status of a national standard, either by publication of an identical
text or by endorsement, at the latest by August 2011, and conflicting national standards shall be withdrawn at
the latest by August 2011.
Attention is drawn to the possibility that some of the elements of this document may be the subject of patent
rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.
This document supersedes EN ISO 14155-1:2009 and EN ISO 14155-2:2009.
This document has been prepared under a mandate given to CEN by the European Commission and the
European Free Trade Association, and supports essential requirements of EU Directive(s).
For relationship with EU Directives, see informative Annexes ZA and ZB, which are an integral part of this
document.
According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following
countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia,
Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain,
Sweden, Switzerland and the United Kingdom.
Endorsement notice
The text of ISO 14155:2011 has been approved by CEN as a EN ISO 14155:2011 without any modification.
Annex ZA
(informative)
Relationship between this European Standard and the Essential
Requirements of EU Directive 93/42/EEC on Medical Devices
This European Standard has been prepared under a mandate given to CEN by the European Commission
and the European Free Trade Association to provide a means of conforming to Essential Requirements of the
New Approach Directive 93/42/EEC on Medical Devices
Once this standard is cited in the Official Journal of the European Union under that Directive and has been
implemented as a national standard in at least one Member State, compliance with the normative clauses of
this standard confers, within the limits of the scope of this standard, a presumption of conformity with the
corresponding Essential Requirements of that Directive and associated EFTA regulations.
NOTE This standard is specifically intended to provide a means for getting presumption of conformity to the part of
Essential Requirement 6a that refers to clinical investigations, as developed in Annex X, 2nd part (2.1 to 2.3.7) of the
above-mentioned directive.
WARNING — Other requirements and other EU Directives may be applicable to the product(s) falling
within the scope of this standard.

Annex ZB
(informative)
Relationship between this European Standard and the Essential
Requirements of EU Directive 90/385/EEC
on active implantable medical devices
This European Standard has been prepared under a mandate given to CEN by the European Commission
and the European Free Trade Association to provide a means of conforming to Essential Requirements of the
New Approach Directive 93/42/EEC on Medical Devices
Once this standard is cited in the Official Journal of the European Union under that Directive and has been
implemented as a national standard in at least one Member State, compliance with the normative clauses of
this standard confers, within the limits of the scope of this standard, a presumption of conformity with the
corresponding Essential Requirements of that Directive and associated EFTA regulations.
NOTE This standard is specifically intended to provide a means for getting presumption of conformity to the part of
Essential Requirement 5. that refers to clinical investigations, as developed in Annex 7, 2nd part (2.1 to 2.3.7) of the above
mentioned directive.
WARNING — Other requirements and other EU Directives may be applicable to the product(s) falling
within the scope of this standard.
INTERNATIONAL ISO
STANDARD 14155
Second edition
2011-02-01
Clinical investigation of medical devices
for human subjects — Good clinical
practice
Investigation clinique des dispositifs médicaux pour sujets humains —
Bonnes pratiques cliniques
Reference number
ISO 14155:2011(E)
©
ISO 2011
ISO 14155:2011(E)
PDF disclaimer
This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but
shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In
downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat
accepts no liability in this area.
Adobe is a trademark of Adobe Systems Incorporated.
Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation
parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In
the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.

©  ISO 2011
All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means,
electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or
ISO's member body in the country of the requester.
ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org
Published in Switzerland
ii © ISO 2011 – All rights reserved

ISO 14155:2011(E)
Contents Page
Foreword .v
1 Scope.1
2 Normative references.1
3 Terms and definitions .2
4 Ethical considerations .7
4.1 General .7
4.2 Improper influence or inducement .8
4.3 Compensation and additional health care.8
4.4 Responsibilities.8
4.5 Communication with the ethics committee (EC).8
4.5.1 General .8
4.5.2 Initial EC submission .8
4.5.3 Information to be obtained from the EC.9
4.5.4 Continuing communication with the EC .9
4.5.5 Continuing information to be obtained from the EC .9
4.6 Vulnerable populations.9
4.7 Informed consent .10
4.7.1 General .10
4.7.2 Process of obtaining informed consent.10
4.7.3 Special circumstances for informed consent .10
4.7.4 Information to be provided to the subject .11
4.7.5 Informed consent signature .13
4.7.6 New information .13
5 Clinical investigation planning .14
5.1 General .14
5.2 Risk evaluation .14
5.3 Justification for the design of the clinical investigation.14
5.4 Clinical investigation plan (CIP).14
5.5 Investigator's brochure (IB).15
5.6 Case report forms (CRFs).15
5.7 Monitoring plan.15
5.8 Investigation site selection .15
5.9 Agreement(s) .15
5.10 Labelling.15
5.11 Data monitoring committee (DMC) .16
6 Clinical investigation conduct .16
6.1 General .16
6.2 Investigation site initiation .16
6.3 Investigation site monitoring .16
6.4 Adverse events and device deficiencies.16
6.4.1 Adverse events.16
6.4.2 Device deficiencies .16
6.5 Clinical investigation documents and documentation.17
6.5.1 Amendments.17
6.5.2 Subject identification log.17
6.5.3 Source documents .17
6.6 Additional members of the investigation site team.17
6.7 Subject privacy and confidentiality of data .17
6.8 Document and data control.18
ISO 14155:2011(E)
6.8.1 Traceability of documents and data . 18
6.8.2 Recording of data . 18
6.8.3 Electronic clinical data systems . 18
6.9 Investigational device accountability . 19
6.10 Accounting for subjects. 19
6.11 Auditing . 19
7 Suspension, termination and close-out of the clinical investigation. 20
7.1 Suspension or premature termination of the clinical investigation. 20
7.1.1 Procedure for suspension or premature termination . 20
7.1.2 Procedure for resuming the clinical investigation after temporary suspension . 21
7.2 Routine close-out. 21
7.3 Clinical investigation report . 21
7.4 Document retention. 22
8 Responsibilities of the sponsor . 22
8.1 Clinical quality assurance and quality control . 22
8.2 Clinical investigation planning and conduct . 23
8.2.1 Selection of clinical personnel. 23
8.2.2 Preparation of documents and materials. 23
8.2.3 Conduct of clinical investigation . 24
8.2.4 Monitoring . 24
8.2.5 Safety evaluation and reporting. 27
8.2.6 Clinical investigation close-out. 27
8.3 Outsourcing of duties and functions. 28
8.4 Communication with regulatory authorities . 28
9 Responsibilities of the principal investigator. 28
9.1 General. 28
9.2 Qualification of the principal investigator. 28
9.3 Qualification of investigation site . 29
9.4 Communication with the EC . 29
9.5 Informed consent process. 29
9.6 Compliance with the CIP. 29
9.7 Medical care of subjects . 30
9.8 Safety reporting . 31
Annex A (normative) Clinical investigation plan (CIP). 32
Annex B (normative) Investigator's brochure (IB). 39
Annex C (informative) Case report forms (CRFs) . 41
Annex D (informative) Clinical investigation report. 43
Annex E (informative) Essential clinical investigation documents. 48
Annex F (informative) Adverse event categorization . 55
Bibliography. 58

iv © ISO 2011 – All rights reserved

ISO 14155:2011(E)
Foreword
ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies
(ISO member bodies). The work of preparing International Standards is normally carried out through ISO
technical committees. Each member body interested in a subject for which a technical committee has been
established has the right to be represented on that committee. International organizations, governmental and
non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the
International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.
International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.
The main task of technical committees is to prepare International Standards. Draft International Standards
adopted by the technical committees are circulated to the member bodies for voting. Publication as an
International Standard requires approval by at least 75 % of the member bodies casting a vote.
Attention is drawn to the possibility that some of the elements of this document may be the subject of patent
rights. ISO shall not be held responsible for identifying any or all such patent rights.
ISO 14155 was prepared by Technical Committee ISO/TC 194, Biological evaluation of medical devices.
This second edition cancels and replaces the first edition of ISO 14155-1:2003 and the first edition of
ISO 14155-2:2003, which have been technically revised.
INTERNATIONAL STANDARD ISO 14155:2011(E)

Clinical investigation of medical devices for human subjects —
Good clinical practice
1 Scope
This International Standard addresses good clinical practice for the design, conduct, recording and reporting
of clinical investigations carried out in human subjects to assess the safety or performance of medical devices
for regulatory purposes.
The principles set forth in this International Standard also apply to all other clinical investigations and should
be followed as far as possible, considering the nature of the clinical investigation and the requirements of
national regulations.
This International Standard specifies general requirements intended to
⎯ protect the rights, safety and well-being of human subjects,
⎯ ensure the scientific conduct of the clinical investigation and the credibility of the clinical investigation
results,
⎯ define the responsibilities of the sponsor and principal investigator, and
⎯ assist sponsors, investigators, ethics committees, regulatory authorities and other bodies involved in the
conformity assessment of medical devices.
It does not apply to in vitro diagnostic medical devices.
NOTE Standards developed by ISO/TC 194 are intended to be applied to medical devices. Users of this International
Standard will need to consider whether other standards and/or requirements also apply to the investigational device(s)
under consideration.
2 Normative references
The following referenced documents are indispensable for the application of this document. For dated
references, only the edition cited applies. For undated references, the latest edition of the referenced
document (including any amendments) applies.
ISO 14971:2007, Medical devices — Application of risk management to medical devices
ISO 14155:2011(E)
3 Terms and definitions
For the purposes of this document, the following terms and definitions apply.
3.1
adverse device effect
ADE
adverse event related to the use of an investigational medical device
NOTE 1 This definition includes adverse events resulting from insufficient or inadequate instructions for use,
deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.
NOTE 2 This definition includes any event resulting from use error or from intentional misuse of the investigational
medical device.
3.2
adverse event
AE
any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal
laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical
device
NOTE 1 This definition includes events related to the investigational medical device or the comparator.
NOTE 2 This definition includes events related to the procedures involved.
NOTE 3 For users or other persons, this definition is restricted to events related to investigational medical devices.
3.3
audit
systematic independent examination of activities and documents related to clinical investigation to determine
whether these activities were conducted, and the data recorded, analysed and accurately reported, according
to the CIP, standard operating procedures, this International Standard and applicable regulatory requirements
3.4
blinding/masking
procedure in which one or more parties to the clinical investigation are kept unaware of the treatment
assignment(s)
NOTE Single blinding usually refers to the subject(s) being unaware of the treatment assignment(s). Double blinding
usually refers to the subject(s), investigator(s), monitor and, in some cases, centralized assessors being unaware of the
treatment assignment(s).
3.5
case report forms
CRFs
set of printed, optical or electronic documents for each subject on which information to be reported to the
sponsor is recorded, as required by the CIP
3.6
clinical investigation
systematic investigation in one or more human subjects, undertaken to assess the safety or performance of a
medical device
NOTE “Clinical trial” or “clinical study” are synonymous with “clinical investigation”.
2 © ISO 2011 – All rights reserved

ISO 14155:2011(E)
3.7
clinical investigation plan
CIP
document that state(s) the rationale, objectives, design and proposed analysis, methodology, monitoring,
conduct and record-keeping of the clinical investigation
NOTE The term “protocol” is synonymous with “CIP”. However, protocol has many different meanings, some not
related to clinical investigation, and these can differ from country to country. Therefore, the term CIP is used in this
International Standard.
3.8
clinical investigation report
document describing the design, execution, statistical analysis and results of a clinical investigation
3.9
clinical performance
behaviour of a medical device or response of the subject(s) to that medical device in relation to its intended
use, when correctly applied to appropriate subject(s)
3.10
comparator
medical device, therapy (e.g. active control), placebo or no treatment, used in the reference group in a clinical
investigation
3.11
contract research organization
CRO
person or organization contracted by the sponsor to perform one or more of the sponsor's clinical
investigation-related duties and functions
3.12
coordinating investigator
investigator who is appointed by the sponsor to coordinate work in a multicentre clinical investigation
3.13
data monitoring committee
DMC
independent committee that may be established by the sponsor to assess, at intervals, the progress of the
clinical investigation, the safety data or the critical performance endpoints and to recommend the sponsor
whether to continue, suspend, modify, or stop the clinical investigation
NOTE Examples of DMCs are “data safety monitoring board (DSMB)” or “data safety monitoring committee (DSMC)”.
3.14
deviation
instance(s) of failure to follow, intentionally or unintentionally, the requirements of the CIP
3.15
device deficiency
inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance
NOTE Device deficiencies include malfunctions, use errors, and inadequate labelling.
3.16
endpoint(s)
〈primary〉 principal indicator(s) used for assessing the primary hypothesis of a clinical investigation
3.17
endpoint(s)
〈secondary〉 indicator(s) used for assessing the secondary hypotheses of a clinical investigation
ISO 14155:2011(E)
3.18
ethics committee
EC
independent body whose responsibility it is to review clinical investigations in order to protect the rights, safety
and well-being of human subjects participating in a clinical investigation
NOTE For the purposes of this International Standard, “ethics committee” is synonymous with “research ethics
committee”, “independent ethics committee” or “institutional review board”. The regulatory requirements pertaining to
ethics committees or similar institutions vary by country or region.
3.19
hypothesis
testable statement, resulting from the objective, regarding the investigational medical device safety or
performance that is used to design the clinical investigation and that can be accepted or rejected based on
results of the clinical investigation and statistical calculations
NOTE The primary hypothesis is the determinant of the investigational medical device safety or performance
parameters and is usually used to calculate the sample size. Secondary hypotheses concerning other points of interest
can also be evaluated.
3.20
independent
not involved in the conduct of a clinical investigation, except for their specifically assigned responsibilities, in
order to avoid bias or a conflict of interest
3.21
informed consent process
process by which an individual is provided information and is asked to voluntarily participate in a clinical
investigation
NOTE Informed consent is documented by means of a written, signed and dated informed consent form.
3.22
investigation site
institution or site where the clinical investigation is carried out
NOTE For the purpose of this International Standard, “investigation site” is synonymous with “investigation centre”.
3.23
investigational medical device
medical device being assessed for safety or performance in a clinical investigation
NOTE 1 This includes medical devices already on the market, that are being evaluated for new intended uses, new
populations, new materials or design changes.
NOTE 2 In this International Standard, the terms “investigational medical device” and “investigational device” are used
interchangeably.
3.24
investigator
individual member of the investigation site team designated and supervised by the principal investigator at an
investigation site to perform critical clinical-investigation-related procedures or to make important clinical-
investigation-related decisions
NOTE An individual member of the investigation site team can also be called “sub-investigator” or
“co-investigator”.
4 © ISO 2011 – All rights reserved

ISO 14155:2011(E)
3.25
investigator's brochure
IB
compilation of the current clinical and non-clinical information on the investigational medical device(s),
relevant to the clinical investigation
3.26
legally authorized representative
individual or judicial or other body authorized under applicable law to consent, on behalf of a prospective
subject, to the subject's participation in the clinical investigation
3.27
malfunction
failure of an investigational medical device to perform in accordance with its intended purpose when used in
accordance with the instructions for use or CIP
3.28
medical device
any instrument, apparatus, implement, machine, appliance, implant, software, material, or other similar or
related article
a) intended by the manufacturer to be used, alone or in combination, for human beings for one or more of
the specific purpose(s) of
1) diagnosis, prevention, monitoring, treatment or alleviation of disease,
2) diagnosis, monitoring, treatment, alleviation of, or compensation for, an injury,
3) investigation, replacement, modification, or support of the anatomy or of a physiological process,
4) supporting or sustaining life,
5) control of conception,
6) disinfection of medical devices, and
b) which does not achieve its primary intended action in or on the human body by pharmacological,
immunological or metabolic means, but which may be assisted in its intended function by such means
NOTE The term “medical device” is usually defined by national regulations. For the purposes of this International
[1]
Standard, this definition does not list “in vitro diagnostic medical devices” (see ISO 13485:2003, definition 3.7 ).
3.29
monitoring
act of overseeing the progress of a clinical investigation and to ensure that it is conducted, recorded, and
reported in accordance with the CIP, written procedures, this International Standard, and the applicable
regulatory requirements
3.30
multicentre investigation
clinical investigation that is conducted according to a single CIP and takes place at two or more investigation
sites
3.31
objective
main purpose for conducting the clinical investigation
ISO 14155:2011(E)
3.32
point of enrolment
time at which, following recruitment, a subject signs and dates the informed consent form
3.33
principal investigator
qualified person responsible for conducting the clinical investigation at an investigation site
NOTE 1 If a clinical investigation is conducted by a team of individuals at an investigation site, the principal investigator
is responsible for leading the team.
NOTE 2 Whether this is the responsibility of an individual or an institution can depend on national regulations.
3.34
randomization
process of assigning subjects to the investigational medical device or comparator groups using an established
recognized statistical methodology to determine the assignment in order to reduce bias
3.35
recruitment
active efforts to identify subjects who may be suitable for enrolment into the clinical investigation
3.36
serious adverse device effect
SADE
adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event
3.37
serious adverse event
SAE
adverse event that
a) led to death,
b) led to serious deterioration in the health of the subject, that either resulted in
1) a life-threatening illness or injury, or
2) a permanent impairment of a body structure or a body function, or
3) in-patient or prolonged hospitalization, or
4) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment
to a body structure or a body function,
c) led to foetal distress, foetal death or a congenital abnormality or birth defect
NOTE Planned hospitalization for a pre-existing condition, or a procedure required by the CIP, without serious
deterioration in health, is not considered a serious adverse event.
3.38
source data
all information in original records, certified copies of original records of clinical findings, observations, or other
activities in a clinical investigation, necessary for the reconstruction and evaluation of the clinical investigation
3.39
source document
printed, optical or electronic document containing source data
EXAMPLES Hospital records, laboratory notes, device accountability records, photographic negatives, radiographs,
records kept at the investigation site, at the laboratories and at the medico-technical departments involved in the clinical
investigation.
6 © ISO 2011 – All rights reserved

ISO 14155:2011(E)
3.40
sponsor
individual or organization taking responsibility and liability for the initiation or implementation of a clinical
investigation
NOTE When an investigator initiates, implements and takes full responsibility for the clinical investigation, the
investigator also assumes the role of the sponsor and is identified as the sponsor-investigator.
3.41
subject
individual who participates in a clinical investigation
NOTE A subject can be either a healthy volunteer or a patient.
3.42
unanticipated serious adverse device effect
USADE
serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the
current version of the risk analysis report
NOTE Anticipated serious adverse device effect (ASADE) is an effect which by its nature, incidence, severity or
outcome has been identified in the risk analysis report.
3.43
use error
act or omission of an act that results in a different medical device response than intended by the manufacturer
or expected by the user
NOTE 1 Use error includes slips, lapses, and mistakes.
NOTE 2 An unexpected physiological response of the subject does not in itself constitute a use error.
[ISO 14971:2007, definition 2.27]
3.44
vulnerable subject
individual whose willingness to volunteer in a clinical investigation could be unduly influenced by the
expectation, whether justified or not, of benefits associated with participation or of retaliatory response from
senior members of a hierarchy in case of refusal to participate
EXAMPLE Individuals with lack of or loss of autonomy due to immaturity or through mental disability, persons in
nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, homeless
persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable subjects include, for
example, members of a group with a hierarchical structure such as university students, subordinate hospital and
laboratory personnel, employees of the sponsor, members of the armed forces, and persons kept in detention.
4 Ethical considerations
4.1 General
Clinical investigations shall be conducted in accordance with the ethical principles that have their origin in the
Declaration of Helsinki (see Reference [8]). These principles protect the rights, safety and well-being of human
subjects, which are the most important considerations and shall prevail over interests of science and society.
These principles shall be understood, observed, and applied at every step in the clinical investigation.
ISO 14155:2011(E)
4.2 Improper influence or inducement
The sponsor shall avoid improper influence on, or inducement of, the subject, monitor, any investigator(s) or
other parties participating in, or contributing to, the clinical investigation.
All investigators shall avoid improper influence on or inducement of the subject, sponsor, monitor, other
investigator(s) or other parties participating in or contributing to the clinical investigation.
4.3 Compensation and additional health care
Compensating subjects for costs resulting from participation in the clinical investigation (e.g. transportation)
may be appropriate if allowed by national regulations, but the compensation shall not be so large as to unduly
encourage the subjects to participate.
Arrangements for additional health care for subjects who suffer from an adverse event as a result of
participating in the clinical investigation shall be made and documented.
NOTE Such arrangements can be subject to national regulations.
4.4 Responsibilities
All parties involved in the conduct of the clinical investigation shall share the responsibility for its ethical
conduct in accordance with their respective roles in the clinical investigation.
4.5 Communication with the ethics committee (EC)
4.5.1 General
If national or regional EC requirements are less strict than the requirements of this International Standard, the
sponsor shall apply the requirements of this International Standard to the greatest extent possible, irrespective
of any lesser requirements, and shall record such efforts.
4.5.2 Initial EC submission
As a minimum, the following information and any amendments shall be provided to the EC:
a) CIP;
b) IB or equivalent documentation;
c) informed consent form and any other written information to be provided to subjects;
d) procedures for recruiting subjects and advertising materials, if any;
e) a copy of the curriculum vitae (CV) of the principal investigator(s) for which the EC has oversight.
The following documents might also need to be provided to the EC depending on the clinical investigation
design and national or regional requirements:
f) sample or draft CRFs, including other data collection tools, as required by the CIP;
g) documents related to payments and compensation available to subjects;
h) proposed compensation to the institution or principal investigator;
i) documentation related to any conflict of interest, including financial, on the part of an investigator;
j) evidence of the clinical investigation insurance.
8 © ISO 2011 – All rights reserved

ISO 14155:2011(E)
4.5.3 Information to be obtained from the EC
Prior to commencing the clinical investigation, th
...